Viridian Therapeutics, Inc. (VRDN) on Tuesday announced positive topline results from the Phase 3 REVEAL-2 study of elegrobart in patients with chronic thyroid eye disease, sending its shares up more than 25% in pre-market trading.
Tuesday, Eli Lilly and Company (LLY) announced new long-term data from the LUCENT-3 open-label extension study in patients with moderately to severely active ulcerative colitis treated with Omvoh. The study showed that 63.5 percent of Omvoh-treated patients who achieved disease clearance at one year...
Cellectar Biosciences, Inc. (CLRB) on Tuesday announced positive 12-month follow-up data from its Phase 2b CLOVER WaM study evaluating iopofosine I 131 in patients with Waldenström acroglobulinemia, a rare, slow-growing blood cancer. Shares rose more than 80% in pre-market trading.
Johnson & Johnson (JNJ) on Monday reported positive results from a network meta-analysis comparing Caplyta with other FDA-approved atypical antipsychotics used as add-on treatments for major depressive disorder in adults. The analysis, based on data from 10 registrational studies, found that Caplyta...
Monday, Takeda Pharmaceutical Company Limited (TAK) announced positive topline data from TAK-881-3001, a pivotal Phase 2/3 clinical trial evaluating TAK-881 in patients with Primary Immunodeficiency Disease or PID. The trial evaluated the pharmacokinetic, efficacy, safety, tolerability and immunogenicity...
Pfizer Inc. (PFE) on Wednesday reported positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO in adults with relapsed or refractory multiple myeloma who had received at least one prior line of treatment. The study met its primary endpoint, showing a statistically significant...
AbbVie Inc. (ABBV) on Tuesday reported positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study, showing that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis. The study met its primary endpoint, with Rinvoq demonstrating superiority over...
Mirum Pharmaceuticals Inc. (MIRM) on Monday said the primary endpoint was met in the Phase 2b portion of its AZURE-1 study evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). At Week 24, brelovitug showed strong antiviral activity, with 100% of patients in the 300 mg weekly...
CorMedix Inc. (CRMD), Monday announced positive Phase III topline results from the global ReSPECT clinical trial, evaluating REZZAYO for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation. The multicenter, randomized, double-blind...
Intellia Therapeutics, Inc. (NTLA) on Monday reported positive topline results from its Phase 3 HAELO trial of lonvo-z, a CRISPR-based gene editing therapy for Hereditary angioedema. The study met its primary goal.
Oruka Therapeutics, Inc. (ORKA) on Monday reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. The company's shares rose more than 20% in pre-market trading.
Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with generalized myasthenia gravis reinforcing the efficacy, sustained disease control and safety profile of IMAAVY. Through 120 weeks of follow-up,...
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.